Hans Wigzell - Karolinska Development Insider

Karolinska Development AB -- Sweden Stock  

SEK 5.20  0.04  0.78%

Independent Chairman of the Board

Dr. Hans Wigzell, M.D., Ph.D. was Chairman of the Board of Directors at Karolinska Development AB since December 29, 2017. He was Independent Director of the Company since 2006. He no longer serves as Independent Chairman of the Board effective as of September 30, 2013. He is also Chairman of Rhenman Partner Asset Management AB and Cadila Pharmaceuticals Sweden Aktieboag, and Member of the Boards of Sarepta Therapeutics Inc. and RaySearch Laboratories AB. He is Member of The Royal Swedish Academy of Engineering Sciences and of the Royal Swedish Academy of Sciences. His previous assignments include, among others, President of Karolinska Institutet Nobel Committee, and President of Karolinska Institutet and Director General of the Smittskyddsinstitutet. He is Professor Emeritus of Immunology and Medical Doctor.
Age: 79  Chairman Since 2017  Ph.D    
46 8 52 48 60 70  http://www.karolinskadevelopment.com

Management Efficiency

The company has return on total asset (ROA) of (3.86) % which means that it has lost $3.86 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 120.96 % meaning that it generated $120.96 on every $100 dollars invested by stockholders.
The company has accumulated 379.18 M in total debt with debt to equity ratio (D/E) of 141.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karolinska Development AB has Current Ratio of 13.84 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Karolinska Development AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. Karolinska Development AB was founded in 2003 and is headquartered in Stockholm, Sweden. Karolinska Development operates under Pharmaceuticals And Biosciences classification in Sweden and traded on Stockholm Stock Exchange exchange.Karolinska Development AB (KDEV) is traded on Stockholm Stock Exchange in Sweden. It is located in Tomtebodav?gen 23 A and employs 13 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Karolinska Development AB to your portfolio

Top Management

Karolinska Development AB Leadership Team
Hans Wigzell, Chairman, Ph.D
Elisabet Gimbringer, Executive
Carl Sundberg, Director
Magnus Persson, Director, Ph.D
Jim Heusden, CEO, Ph.D
Maria Ferm, Executive
HansOlov Olsson, Director, Ph.D
Theresa Tse, Director
Viktor Drvota, Executive, Ph.D
Eva Montgomerie, Executive
Michael Owens, Executive
Yan Cheng, President
Ulf Richenberg, Executive
Niclas Adler, Director
Tse Ping, Director, Ph.D
Christian Tange, CFO, MBA
Daniel Bolanowski, Executive
Terje Kalland, Executive, Ph.D
Vladimir Artamonov, Director, MBA
Felicia Rittemar, Executive
AnnSofie Sternas, President
Anders Harfstrand, Director, Ph.D
Bo Hansen, Chairman, Ph.D
Fredrik Jarrsten, CFO
Khalid Islam, Director, Ph.D
Gunilla Ekstrom, President, Ph.D
Henrijette Richter, Director

Stock Performance

Karolinska Development Performance Indicators